NASDAQ: BRNS - Barinthus Biotherapeutics plc

छह महीने के लिए लाभप्रदता: -26.06%
भाग प्रतिफल: 0.00%

पदोन्नति कार्यक्रम Barinthus Biotherapeutics plc


कंपनी के बारे में Barinthus Biotherapeutics plc

Vaccitech plc, a clinical-stage biopharmaceutical company, engages in the discovery and development of novel T cell immunotherapeutics and vaccines for the treatment and prevention of infectious diseases and cancers.

अधिक जानकारी
The company's therapeutic programs include VTP-300, which is in Phase 1/2a clinical trial for the treatment of chronic hepatitis B infection; VTP-200 that is in Phase 1/2a clinical trial for the treatment of human papilloma virus infection; VTP-850, which is in Phase 1/2 clinical trial for the treatment of prostate cancer; and VTP-600 that is in Phase 1/2a clinical trial for the treatment of non-small cell lung cancer. Its prophylactic programs include VTP-400, which is in preclinical stage for the prevention of herpes zoster or shingles; VTP-500 that has completed Phase 1 clinical trial for the prevention of Middle East respiratory syndrome; and Vaxzevria, a prophylactic vaccine for the prevention of COVID-19 infection. The company was formerly known as Vaccitech plc, a clinical-stage biopharmaceutical company, engages in the discovery and development of novel immunotherapeutics and vaccines for the treatment and prevention of infectious and autoimmunity diseases, and cancers. The company's therapeutic programs include VTP-300, which is in Phase 2a clinical trial for the treatment of chronic hepatitis B infection; VTP-200 that is in Phase 1b/2 clinical trial for the treatment of human papilloma virus infection; VTP-850, which is in Phase 1/2 clinical trial for the treatment of prostate cancer; and VTP-600 that is in Phase 1/2a clinical trial for the treatment of non-small cell lung cancer. Its prophylactic programs include VTP-400, which is in preclinical stage for the prevention of herpes zoster or shingles; VTP-500 that has completed Phase 1 clinical trial for the prevention of Middle East respiratory syndrome; and Vaxzevria, a prophylactic vaccine for the prevention of COVID-19 infection. The company was formerly known as Vaccitech Rx Limited and changed its name to Vaccitech plc in March 2021. Vaccitech plc was founded in 2016 and is headquartered in Oxford, the United Kingdom.Vaccitech Rx Limited and changed its name to Vaccitech plc in March 2021. Vaccitech plc was founded in 2016 and is headquartered in Oxford, the United Kingdom.

IPO date 2021-04-30
ISIN US91864C1071
Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета usd
Сайт https://www.barinthusbio.com
Цена ао 2.4
प्रति दिन मूल्य परिवर्तन: 0% (1.06)
प्रति सप्ताह मूल्य परिवर्तन: -4.5% (1.11)
प्रति माह मूल्य परिवर्तन: +11.02% (0.9548)
3 महीने में कीमत में बदलाव: -10.18% (1.1801)
छह महीने में कीमत में बदलाव: -26.06% (1.4336)
प्रति वर्ष मूल्य परिवर्तन: -71.27% (3.69)
3 वर्षों में मूल्य परिवर्तन: -88.38% (9.12)
5 वर्षों में मूल्य परिवर्तन: 0% (1.06)
10 वर्षों में मूल्य परिवर्तन: 0% (1.06)
वर्ष की शुरुआत से मूल्य परिवर्तन: +19.37% (0.888)

बहुत मूल्यवान समझना

नाम अर्थ श्रेणी
P/S 167.83 1
P/BV 0.7226 10
P/E 0 0
EV/EBITDA -0.0845 0
कुल: 5.13

क्षमता

नाम अर्थ श्रेणी
ROA, % -34.33 0
ROE, % -39.42 0
कुल: 0

लाभांश

नाम अर्थ श्रेणी
Div yield, % 0 0
DSI 0 0
कुल: 0

कर्तव्य

नाम अर्थ श्रेणी
Debt/EBITDA -0.1826 10
कुल: 9.4

विकास का आवेग

नाम अर्थ श्रेणी
लाभप्रदता Revenue, % -88.38 0
लाभप्रदता Ebitda, % 179.78 10
लाभप्रदता EPS, % 212.67 10
कुल: 8

संस्थानों आयतन शेयर करना, %
M&G INVESTMENT MANAGEMENT LTD 5197349 13.48
Alphabet Inc. 1513644 3.92
HSG Holding Ltd. 1420473 3.68
DC Funds, LP 642204 1.67
BlueCrest Capital Management Ltd 542673 1.41
Baird Financial Group, Inc. 196296 0.51
Johns Hopkins University 107968 0.28
Ipswich Investment Management Company, INc. 23075 0.06
Renaissance Technologies, LLC 21400 0.06
Morgan Stanley 21215 0.06

पर्यवेक्षक नौकरी का शीर्षक भुगतान जन्म का साल
Mr. William J. Enright MBA CEO & Director 969.44k 1962 (63 वर्ष)
Ms. Sarah Gilbert Co-Founder 48.98k
Mr. Adrian Hill Ph.D. Co-Founder & Scientific Advisor 61.61k
Ms. Gemma Brown CFO & Company Secretary N/A 1991 (34 वर्ष)
Dr. Nadege Pelletier Ph.D. Chief Scientific Officer 593.48k 1979 (46 साल)
Mr. Graham Griffiths Chief Operating Officer 522.23k 1979 (46 साल)
Ms. Elizabeth Eagling-Vose M.B.A. Head of Clinical Operations N/A
Bernie McDonald Head of IP N/A
Geoffrey Lynn Senior Vice President of Synthetic Immunotherapies N/A
Dr. Leon Hooftman M.D. Chief Medical Officer

पता: United Kingdom, Harwell OX DF, Zeus Building - Google मानचित्र में खोलें, यांडेक्स मानचित्र खोलें
वेबसाइट: https://www.barinthusbio.com